TAO SHEN to Proto-Oncogene Proteins c-ret
This is a "connection" page, showing publications TAO SHEN has written about Proto-Oncogene Proteins c-ret.
Connection Strength
0.620
-
Targeting Oncogenic RET Kinase by Simultaneously Inhibiting Kinase Activity and Degrading the Protein. J Med Chem. 2025 01 09; 68(1):81-94.
Score: 0.224
-
Structural basis of resistance of mutant RET protein-tyrosine kinase to its inhibitors nintedanib and vandetanib. J Biol Chem. 2019 07 05; 294(27):10428-10437.
Score: 0.152
-
Drug resistance profiles of mutations in the RET kinase domain. Br J Pharmacol. 2018 09; 175(17):3504-3515.
Score: 0.143
-
Targeting RET Solvent-Front Mutants with Alkynyl Nicotinamide-Based Inhibitors. Mol Cancer Ther. 2023 06 01; 22(6):717-725.
Score: 0.050
-
Progress and challenges in RET-targeted cancer therapy. Front Med. 2023 Apr; 17(2):207-219.
Score: 0.050